According to Zacks, “Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company’s product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md. “
Separately, Piper Sandler lowered their target price on shares of Sensei Biotherapeutics from $12.00 to $10.00 and set an overweight rating on the stock in a report on Thursday, March 10th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Buy and an average target price of $10.96.
Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Equities research analysts anticipate that Sensei Biotherapeutics will post -1.64 earnings per share for the current year.
In other news, Director James Peyer bought 15,000 shares of the company’s stock in a transaction that occurred on Thursday, February 24th. The stock was bought at an average price of $3.63 per share, for a total transaction of $54,450.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have acquired a total of 18,703 shares of company stock valued at $67,300 in the last ninety days.
A number of hedge funds have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Sensei Biotherapeutics during the 1st quarter worth about $25,000. Royal Bank of Canada lifted its holdings in shares of Sensei Biotherapeutics by 255.1% in the 3rd quarter. Royal Bank of Canada now owns 2,411 shares of the company’s stock valued at $25,000 after buying an additional 1,732 shares during the period. Citigroup Inc. lifted its holdings in shares of Sensei Biotherapeutics by 565.5% in the 3rd quarter. Citigroup Inc. now owns 2,409 shares of the company’s stock valued at $25,000 after buying an additional 2,047 shares during the period. Raymond James & Associates acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $30,000. Finally, Leo Brokerage LLC acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $34,000. 11.10% of the stock is currently owned by institutional investors.
About Sensei Biotherapeutics (Get Rating)
Sensei Biotherapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.
- Get a free copy of the StockNews.com research report on Sensei Biotherapeutics (SNSE)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.